Health follow-up for children born after assisted reproductive techniques
Enhancing Algorithms for the Management of Children Conceived by Assisted Reproductive Technologies Based on a Comprehensive Assessment of the Impact of Modern Methods of Conception on Their Health Status
This project will see if children up to 36 months conceived by IVF, ICSI, or frozen embryo transfer have differences in growth, neurological development, or reproductive markers compared with expected norms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 0 Months to 3 Years |
| Sex | All |
| Sponsor | Kazakhstan's Medical University "KSPH" Academic / other |
| Locations | 1 site (Almaty) |
| Trial ID | NCT07278960 on ClinicalTrials.gov |
What this trial studies
This observational project will analyze clinical and anamnestic data from about 300 children born after advanced ART methods in Kazakhstan. Investigators will combine a retrospective review of perinatal and parental medication history with in-person assessments of anthropometrics, somatic health, basic neurological screening, and targeted urogenital examinations. Male children in the ICSI subgroup will have reproductive hormones (inhibin B, AMH) measured to characterize endocrine profiles. Results will be used to inform management principles and referral pathways tailored to children conceived by ART.
Who should consider this trial
Good fit: Children from birth up to 36 months conceived by IVF, ICSI, or fresh/frozen embryo transfer with complete perinatal and ART documentation and parental consent, plus consenting mothers (and fathers for ICSI subgroup) willing to provide medical history.
Not a fit: Children older than 36 months, those not conceived via ART, or those without complete perinatal/ART records are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, the study could help clinicians detect early health differences and create tailored follow-up and referral plans for children conceived by ART.
How similar studies have performed: Previous observational studies have reported modest perinatal and growth differences in ART-conceived offspring, but findings on neurological and reproductive outcomes are mixed and remain inconclusive.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For children: * Born as a result of an ART program (IVF, ICSI, FET, or Fresh-ET). * Age at the time of assessment: from birth up to 36 months. * Availability of complete perinatal and medical documentation, including ART cycle characteristics and neonatal outcomes. * Informed consent provided by parents or legal guardians for participation in the study and for biological sample collection (where applicable). For mothers: * History of pregnancy achieved through ART within the territory of Kazakhstan. * Availability of data on pharmacological treatment before and during pregnancy (e.g., hormonal therapy, antithyroid drugs, vitamins, micronutrients). * Willingness to provide anamnestic and perinatal information, and consent for access to medical records. For fathers (in ICSI subgroup): * Documented infertility factor necessitating ICSI. * Agreement to provide relevant medical history and participate in comparative analyses (e.g., endocrine or reproductive parameters of father-son pairs).
Where this trial is running
Almaty
- Международный клинический центр репродуктологии Persona — Almaty, Kazakhstan (Recruiting)
Study contacts
- Study coordinator: Sevara Ilmuratova, PhD
- Email: ilmuratova.s@gmail.com
- Phone: +77778017305
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.